Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (631-640 of 656) with videos related to

Pageof 66
Sort By:
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Journal of the National Cancer Institute|March 14, 2019
Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 CentersClio Dessinioti, Niki Dimou, Alan C Geller, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
Nature Communications|March 5, 2021
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doublingIsmael A Vergara, Christopher P Mintoff, Shahneen Sandhu, et al.
Science Immunology|February 2, 2024
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8<sup>+</sup> T-myeloid cell networks in melanomaDavid Barras, Eleonora Ghisoni, Johanna Chiffelle, et al.
Nature Communications|April 4, 2019
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5<sup>-/-</sup> miceYan Li, Roberto Tinoco, Lisa Elmén, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Pageof 66

Showing results (631-640 of 656) with videos related to

Sort By:
Pageof 66
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Nature|November 26, 2010
COT drives resistance to RAF inhibition through MAP kinase pathway reactivationCory M Johannessen, Jesse S Boehm, So Young Kim, et al.
Journal of the National Cancer Institute|March 14, 2019
Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 CentersClio Dessinioti, Niki Dimou, Alan C Geller, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
Nature Communications|March 5, 2021
Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doublingIsmael A Vergara, Christopher P Mintoff, Shahneen Sandhu, et al.
Science Immunology|February 2, 2024
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8<sup>+</sup> T-myeloid cell networks in melanomaDavid Barras, Eleonora Ghisoni, Johanna Chiffelle, et al.
Nature Communications|April 4, 2019
Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5<sup>-/-</sup> miceYan Li, Roberto Tinoco, Lisa Elmén, et al.
Nature Communications|July 20, 2019
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsFelicity Newell, Yan Kong, James S Wilmott, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Pageof 66